
Insurance Stocks That Balance Growth and Value: 7 Picks
Seven insurance stocks span life, diversified P&C, personal lines, specialty commercial, and brokerage models, including Allstate, Progressive, Hartford, Cincinnati, and CNO.
Everything tagged "insurance" across the TickerSpark archives.

Seven insurance stocks span life, diversified P&C, personal lines, specialty commercial, and brokerage models, including Allstate, Progressive, Hartford, Cincinnati, and CNO.

Willis Towers Watson combines steady fee-based growth with an AI-led efficiency plan that could unlock meaningful margin expansion. The stock looks attractive at 16.7x forward earnings, though debt and execution risk keep the case moderate-risk.

Humana is a medium-term recovery story with scale in Medicare Advantage and a growing CenterWell platform, but near-term margins remain pressured. The report rates the stock Hold as management works toward a 2028 margin reset.

A quieter hurricane season may reduce near-term catastrophe claims, but rising property values, population growth, and repair costs are making every major event more expensive. The better insurance trade is pricing power and exposure discipline, not a seasonal forecast.

Molina Healthcare is a large government-sponsored managed care franchise with a strong balance sheet and a clear growth pipeline, but recent earnings have been pressured by medical cost inflation and contract churn. The report rates MOH a Buy, with upside tied to a recovery in margins and execution on Medicaid, Medicare, and Florida.

Globe Life is a steady compounder with improving health growth, strong cash generation, and a valuation that still looks reasonable versus earnings power.

Travelers did not rip higher on hype. TRV broke out because the quarter showed exactly what investors should want from a property and casualty insurer: elite underwriting, rising investment income, and a valuation that still does not look stretched.

Progressive is still one of the best operators in insurance, and that is exactly why the latest selloff matters. When a stock is priced for near-perfect execution, a combined ratio moving the wrong way and premium growth cooling are enough to justify a reset.

Copart remains a high-quality compounder with elite margins, a fortress balance sheet, and durable international growth levers. Near-term revenue growth has slowed, but the stock still screens as a Buy on valuation and cash generation.

Elevance Health is a high-quality managed care franchise taking a deliberate earnings reset in 2026 to protect long-term margins. The stock looks reasonably valued versus its earnings power, with a path to stronger growth in 2027.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime